Zarafonetis CJ, Dabich L, Skovronski JJ, et al. Estudios retrospectivos en esclerodermia: respuesta de la piel al tratamiento con paraaminobenzoato de potasio. Clin Exp Rheumatol. 1988;6:261-268.
Zarafonetis CJ, Dabich L, Negri D, et al. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. J Clin Epidemiol. 1988;41:193-205.
Clegg DO, Reading JC, Mayes MD. Comparación de aminobenzoato de potasio y placebo en el tratamiento de la esclerodermia. J Rheumatol. 1994;21:105-110.
Hasche-Klunder R. Treatment of Peyronie’s disease with para-aminobenzoacidic potassium . Urologe A. 1978;17:224-247.
Carson CC. Paraaminobenzoato de potasio para el tratamiento de la enfermedad de Peyronie: ¿es eficaz? Tech Urol. 1997;3:135-139.
Ludwig G. Evaluation of conservative therapeutic approaches to Peyronie’s disease (fibrotic induration of the penis). Urol Int. 1991;47:236-239.
Sieve BF. The clinical effects of a new B complex factor, para-aminobenzoic acid, on pigmentation and fertility. South Med Surg. 1942;104:135-139.
Physicians’ Desk Reference. Oradell, NJ: Medical Economics Co; 1989.
Kantor GR, Ratz JL. Toxicidad hepática del para-aminobenzoato de potasio. J Am Acad Dermatol. 1985;13:671-672.
Hughes CG. PABA oral y vitiligo . J Am Acad Dermatol. 1983;9:770.
Degowin RL, Eppes RB, Carson PE, et al. The effects of diaphenylsulfone (DDS) against chloroquine-resistant Plasmodium falciparum.Bull World Health Organ. 1966;34:671-681.
Vinnicombe HG, Derrick JP. Dihydropteroate synthase from Streptococcus pneumoniae: characterization of substrate binding order and sulfonamide inhibition. Biochem Biophys Res Commun. 1999;258:752-757.
Weidner W, Hauck EW, Schnitker J et al. Potassium Paraaminobenzoate (POTABAtrade mark) in the Treatment of Peyronie’s Disease: A Prospective, Placebo-Controlled, Randomized Study. Eur Urol. 2005;47:530-6.